Reeve Bryce B, Potosky Arnold L, Smith Ashley Wilder, Han Paul K, Hays Ron D, Davis William W, Arora Neeraj K, Haffer Samuel C, Clauser Steven B
Outcomes Research Branch, Applied Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, EPN 4005, 6130 Executive Blvd, Bethesda, MD 20892-7344, USA.
J Natl Cancer Inst. 2009 Jun 16;101(12):860-8. doi: 10.1093/jnci/djp123. Epub 2009 Jun 9.
The impact of cancer on health-related quality of life (HRQOL) is poorly understood because of the lack of baseline HRQOL status before cancer diagnosis. To our knowledge, this is the first population-based study to quantify the nature and extent of HRQOL changes from before to after cancer diagnosis for nine types of cancer patients and to compare their health with individuals without cancer.
The Surveillance, Epidemiology, and End Results cancer registry data were linked with the Medicare Health Outcomes Survey (MHOS) data; data were collected from Medicare beneficiaries who were aged 65 years and older from 1998 through 2003. Cancer patients (n = 1432; with prostate, breast, colorectal, lung, bladder, endometrial, or kidney cancers; melanoma; or non-Hodgkin lymphoma [NHL]) were selected whose first cancer diagnosis occurred between their baseline and follow-up MHOS assessments. Control subjects without cancer (n = 7160) were matched to cancer patients by use of propensity scores that were estimated from demographics and comorbid medical conditions. Analysis of covariance models were used to estimate changes in HRQOL as assessed with the Medical Outcomes Study Short Form-36 survey (mean score = 50, SD = 10). All statistical tests were two-sided.
Patients with all cancer types (except melanoma and endometrial cancer) reported statistically significant declines in physical health (mean scores: prostate cancer = -3.4, 95% confidence interval [CI] = -2.5 to -4.2; breast cancer = -3.5, 95% CI = -2.5 to -4.5; bladder cancer = -4.3, 95% CI = -2.5 to -6.1; colorectal cancer = -4.4, 95% CI = -3.3 to -5.5; kidney cancer = -5.7, 95% CI = -3.2 to -8.2; NHL = -6.7, 95% CI = -4.4 to -9.1; and lung cancer = -7.5, 95% CI = -5.9 to -9.2) compared with the control subjects (mean score = -1.8, 95% CI = -1.6 to -2.0) (all P < .05). However, only lung (mean score = -5.4, 95% CI = -3.5 to -7.2), colorectal (mean score = -3.5, 95% CI = -2.2 to -4.7), and prostate (mean score = -2.8, 95% CI = -1.8 to -3.7) cancer patients showed statistically significant decreases in mental health relative to the mean change of the control subjects (mean score = -1.2, 95% CI = -0.9 to -1.4) (all P < .05).
These findings provide validation of the specific deleterious effects of cancer on HRQOL and an evidence base for future research and clinical interventions aimed at understanding and remediating these effects.
由于缺乏癌症诊断前的健康相关生活质量(HRQOL)基线状态,癌症对HRQOL的影响尚未得到充分了解。据我们所知,这是第一项基于人群的研究,旨在量化九种癌症患者从癌症诊断前到诊断后HRQOL变化的性质和程度,并将他们的健康状况与无癌症个体进行比较。
监测、流行病学和最终结果癌症登记数据与医疗保险健康结果调查(MHOS)数据相链接;数据收集自1998年至2003年年龄在65岁及以上的医疗保险受益人。选择了癌症患者(n = 1432;患有前列腺癌、乳腺癌、结直肠癌、肺癌、膀胱癌、子宫内膜癌或肾癌;黑色素瘤;或非霍奇金淋巴瘤[NHL]),其首次癌症诊断发生在基线和随访MHOS评估之间。无癌症的对照受试者(n = 7160)通过使用根据人口统计学和合并症估计的倾向得分与癌症患者进行匹配。使用协方差分析模型来估计用医学结果研究简表36调查评估的HRQOL变化(平均得分 = 50,标准差 = 10)。所有统计检验均为双侧检验。
所有癌症类型(黑色素瘤和子宫内膜癌除外)的患者报告称,与对照受试者(平均得分 = -1.8,95%置信区间[CI] = -1.6至 -2.0)相比,身体健康状况有统计学显著下降(平均得分:前列腺癌 = -3.4,95%CI = -2.5至 -4.2;乳腺癌 = -3.5,95%CI = -2.5至 -4.5;膀胱癌 = -4.3,95%CI = -2.5至 -6.1;结直肠癌 = -4.4,95%CI = -3.3至 -5.5;肾癌 = -5.7,95%CI = -3.2至 -8.2;NHL = -6.7,95%CI = -4.4至 -9.1;肺癌 = -7.5,95%CI = -5.9至 -9.2)(所有P <.05)。然而,相对于对照受试者的平均变化(平均得分 = -1.2,95%CI = -0.9至 -1.4),只有肺癌(平均得分 = -5.4,95%CI = -3.5至 -7.2)、结直肠癌(平均得分 = -3.5,95%CI = -2.2至 -4.7)和前列腺癌(平均得分 = -2.8,95%CI = -1.8至 -3.7)患者的心理健康状况有统计学显著下降(所有P <.05)。
这些发现证实了癌症对HRQOL的特定有害影响,并为未来旨在理解和纠正这些影响的研究和临床干预提供了证据基础。